Virpax Pharmaceuticals, Inc. (VRPX) Key Metrics
VRPX valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $994
- Enterprise value
- −$1.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −213.04
VRPX key metrics, 2018–2024
Fiscal year ended December 31, 2024 · U.S. dollarsVRPX returns How much profit the business earns on the capital it uses.
Return on assets−112.1 pts
−215.8%
2024 · hover or tap a bar for each year
20182024
Asset turnover
0.00
2024 · hover or tap a bar for each year
20182024
VRPX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2024 · hover or tap a bar for each year
20182024
Earnings per share
−$2.84
2024 · hover or tap a bar for each year
20182024
Free cash flow per share
−$3,928.38
2024 · hover or tap a bar for each year
20182024
Book value per share
−$0.21
2024 · hover or tap a bar for each year
20182024
Shares outstanding+263.2%
4.3M
2024 · hover or tap a bar for each year
20182024
VRPX financial health Debt, liquidity and how easily interest is covered.
Net debt+$7.6M
−$1.5M
2024 · hover or tap a bar for each year
20182024
Current ratio−49.7%
0.63
2024 · hover or tap a bar for each year
20182024
Interest coverage
-116.4
2024 · hover or tap a bar for each year
20182024
VRPX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VRPX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VRPX key metrics
2018–2024| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.84 | −$12.97 | −$18.32 | −$10.37 | −$9.07 | −$6.58 | −$0.53 |
| Operating cash flow per share | −$3,928.38 | −$8.41 | −$15.24 | −$12.41 | −$2.80 | −$2.17 | −$0.36 |
| Free cash flow per share | −$3,928.38 | −$8.41 | −$15.24 | −$12.41 | −$2.80 | −$2.17 | −$0.36 |
| Cash per share | $0.36 | $7.81 | $16.22 | $31.45 | $0.11 | $0.08 | $0.01 |
| Book value per share | −$0.21 | $1.65 | $14.16 | $32.00 | −$8.53 | −$5.24 | −$0.24 |
| Tangible book value per share | −$0.21 | $1.65 | $14.16 | $32.00 | −$8.53 | −$5.24 | −$0.24 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | — | — | $3.17 | $2.42 | $0.10 |
| Shares outstanding | 4.3M | 1.2M | 1.2M | 1.2M | 495K | 522K | 4.9M |
| Change in shares outstanding | +263.2% | +0.0% | −0.0% | +136.9% | −5.2% | −89.5% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | — | −164.1% | −79.4% | −73.0% | — | — | — |
| Return on assets (ROA) | −215.8% | −103.7% | −72.4% | −60.7% | — | — | — |
| Return on tangible assets | −775.7% | −157.8% | −109.1% | −30.7% | −964.2% | — | — |
| Financial health | |||||||
| Total debt | — | — | — | — | $1.6M | $1.3M | $500,000 |
| Cash & short-term investments | $1.5M | $9.1M | $19.0M | $36.8M | $54,796 | $41,536 | $48,370 |
| Net debt | −$1.5M | −$9.1M | −$19.0M | −$36.8M | $1.5M | $1.2M | $451,630 |
| Debt / assets | — | — | — | — | 3.36 | 27.07 | 8.13 |
| Net debt / EBITDA | — | — | — | −591.74 | 377.70 | — | — |
| Current ratio | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 | 0.02 | 0.05 |
| Quick ratio | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 | 0.02 | 0.05 |
| Interest coverage | -116.4 | — | -112.4 | -129.6 | -28.4 | -25.5 | -175.3 |
| Working capital | −$913,760 | $1.9M | $16.6M | $37.5M | −$3.6M | −$2.7M | −$1.2M |
| Invested capital | −$2.4M | −$7.2M | −$2.4M | $642,753 | −$2.7M | −$1.5M | −$741,094 |
| Tangible asset value | −$913,760 | $1.9M | $16.6M | $37.5M | −$4.2M | −$2.7M | −$1.2M |
| Net current asset value | −$913,760 | $1.9M | $16.6M | $37.5M | −$4.6M | −$2.7M | −$1.2M |
| Graham net-net per share | −$0.22 | $1.24 | $13.58 | $29.67 | −$9.36 | −$5.24 | −$0.24 |
| Capital allocation | |||||||
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | |||||||
| Receivables turnover | — | — | — | — | 0.00 | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | $694 | $694 | $0 |
| Average payables | $9,238 | $18,831 | $28,742 | $20,974 | $12,801 | $5,024 | $6,553 |
| Average inventory | — | — | — | — | — | $3,328 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VRPX's annual financial statements (latest annual report filed March 3, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VRPX valuation and financial ratios
The share count fell 14.0% from 4.9M to 4.3M over 6 years.
See the VRPX income statement, the VRPX chart for price history, or the VRPX stock overview for the latest quote and news.
VRPX key metrics FAQ
What is Virpax Pharmaceuticals's current ratio?
Virpax Pharmaceuticals's current ratio was 0.63 at the end of fiscal 2024: current assets were 0.63 times current liabilities.